Canf Pharmaceuticals is an Israeli biopharmaceutical company developing oral A3 adenosine receptor agonists to treat inflammatory and immune-mediated diseases. The company's lead candidates, Piclidenoson and Namodenoson, have completed Phase II clinical trials in indications such as rheumatoid arthritis and psoriasis, demonstrating favorable safety profiles in over 1,900 patient exposures combined; both compounds have received orphan drug designations for certain indications. The company generates value through its proprietary technology and patent portfolio in A3AR agonists, where no approved competitors currently exist, and its business model depends on obtaining regulatory approval from the FDA and foreign authorities and successfully commercializing these product candidates in inflammatory disease markets.